International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)Constantinos O’Mahony, Perry Elliott, Fatima Jichi et al.|Circulation|2017Cited by 209
Outcome in Phospholamban R14del CarriersIngrid A.W. van Rijsingen, Arthur A.M. Wilde, Judith A. Groeneweg et al.|Circulation Cardiovascular Genetics|2014Cited by 190
Gender-Specific Differences in Major Cardiac Events and Mortality in Lamin A/C Mutation CarriersIngrid A.W. van Rijsingen, Yigal M. Pinto, Eline A. Nannenberg et al.|European Journal of Heart Failure|2012Cited by 148
Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutationsE. Rosalie Witjas‐Paalberends, Jolanda van der Velden, Albert C. van Rossum et al.|Cardiovascular Research|2014Cited by 125
Hypertrophic remodelling in cardiac regulatory myosin light chain (<i>MYL2</i>) founder mutation carriersGodelieve R.F. Claes, Arthur van den Wijngaard, Florence H. J. van Tienen et al.|European Heart Journal|2015Cited by 78